About Oxford Nanopore:Headquartered in Oxford, England, Oxford Nanopore has developed the world’s first and only nanopore DNA sequencer, the MinION, a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, and enabling myriad applications within the traditional laboratory environment and in the field.
About Immunocore：Founded in Oxfordshire with offices in Philadelphia, USA, Immunocore is a world-leading biotechnology company focused on the development of a new class of immunotherapeutic drugs, based on proprietary T Cell Receptor (TCR) technology. The Company is primarily focused in the area of immuno-oncology but the technology also has potential for other conditions including infections and autoimmune diseases. The scientific expertise at Immunocore spans the entire process of drug development, from the discovery and validation of suitable disease targets, through the design and engineering of immune-activating TCR-based drugs, to preclinical, clinical assessment, manufacturing and regulatory affairs.
Clinical and Pipeline
Immunocore’s lead program, IMCgp100, is currently undergoing a pivotal clinical study as a monotherapy for the treatment of patients with metastatic uveal melanomas. Combination studies with IMCgp100 and other immunotherapies, including a Phase I/II study with checkpoint inhibitors durvalumab and tremelimumab from MedImmune (AstraZeneca), for patients with metastatic cutaneous melanoma, are currently recruiting. In addition, IMCgp100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of uveal melanoma.
Acquisition exit - APRIL 2019
About Auris Health, Inc：Co-founded and led by visionary entrepreneur Dr. Frederic Moll, the Redwood City, California, USA-based company has pioneered and integrated the latest advancements in surgical robotics. Auris Health creates platforms that enhance physician capabilities, evolve minimally invasive techniques, and fashion new categories of care that redefines optimal patient outcomes.
About RefleXion Medical：Based in Hayward, California, USA, RefleXion Medical is a medical technology company that has developed the first and only biology-guided radiotherapy system (BgRT) for targeted and revolutionary cancer treatment.
About Potrero Medical: Founded and based in San Francisco, California, USA, Potrero Medical develops monitoring devices to detect subtle changes in various physiological parameters. They provide earlier warnings of sepsis or systemic inflammatory response syndrome and optimizing its treatment by detecting and preventing fluid overload during fluid resuscitation.
About Oxford Nanoimaging: Based in Oxford, England, Oxford Nanoimaging (ONI) manufactures and sells custom microscopes offering super-resolution and single-molecule capabilities to research users. ONI’s objective is to bring the most advanced fluorescence microscopy methods to a whole new community of researchers, for whom such experiments may previously have been inaccessible. In this way, the full potential of single-molecule fluorescence for understanding cells and combating disease at the molecular level can be realized.
About Ultromics Limited: The Oxford, England-headquartered company has been designing world-class cardiology diagnostic aids by leveraging artificial intelligence and one of the world’s largest imaging databases. Its applications analyze all the data points using machine-learning techniques, while having the potential to yield new, objective and highly diagnostic metrics about cardiac function and disease.
The echocardiography software developed by Ultromics drastically improves the diagnosis of coronary heart disease. By extracting more than 80,000 data points from a single echocardiogram image to overcome subjectivity, it increases diagnostic accuracy of coronary heart disease from 80% to >90%, helping cardiologists with the power of artificial intelligence.
About OrganOx: Based in Oxford, England, OrganOx is developing a medical device, the OrganOx metra, that will increase the availability of suitable livers by enabling successful transplantation of organs from non-heart-beating donors and reducing the number of discarded livers. The device operates by maintaining the organ in a fully functioning state during transport and storage, by providing blood flow, oxygen, nutrients and temperature within physiological parameters. This not only enables the liver to be stored safely for a longer period (up to 24 hours) but also provides the surgeon with real-time and cumulative data with which to assess viability and make a decision whether to transplant. This is a major advance over the current method of organ assessment, which is largely subjective.
The OrganOx metra is currently commercially available within the EU. OrganOx is currently engaged in a further pivotal study in the US and a further study at the Queen Elizabeth Hospital, Birmingham to test the viability and transplant potential of marginal livers.
About GI Windows: GI Windows is a clinical-stage medical device company with the guiding principles of focusing on lasting mechanisms of action to treat metabolic diseases, avoiding long-term implants, minimizing delivery tools and procedure complexity, and creating a same day, endosuite procedure without general anesthesia.
About Rarecyte: Based in Seattle, Washington, USA, RareCyte is a life science company that offers high-performance easy to use, next-generation tools for the analysis and capture of rare, individual cells from liquid biopsies and tissue samples. RareCyte’s systems are used by academic institutions and commercial organizations for a range of applications in oncology, prenatal testing and infectious disease.
About Oxford VR：Oxford VR is built on the ground-breaking work of Daniel Freeman, Professor of Clinical Psychology at Oxford University and Consultant Clinical Psychologist, Oxford Health NHS Foundation Trust. Freeman has been one of the pioneers of the use of virtual reality to understand and treat mental health problems, with research funded by the Wellcome Trust, the UK Medical Research Council, and the NHS National Institute of Health Research. Oxford VR’s focus is on developing clinically validated, cost-effective, user-centred cognitive treatments for clinical conditions with significant impact on patients, the health system and wider economy. Our treatments are automated, with the therapy delivered by a virtual coach, enabling us to increase dramatically access to the best therapies. We take a cognitive therapy approach, basing therapeutic techniques on a tested theoretical model of each problem. The automated therapy is therefore tailored for each condition, with its efficacy demonstrated in clinical trials. When VR is done properly, the experience triggers the same psychological and physiological reactions as real-life situations. And that means that what people learn from the VR therapy can help them in the real world.